Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 9
2001 17
2002 21
2003 28
2004 26
2005 31
2006 16
2007 30
2008 46
2009 60
2010 71
2011 86
2012 98
2013 118
2014 149
2015 146
2016 141
2017 137
2018 119
2019 59
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,251 results
Results by year
Filters applied: . Clear all
Page 1
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
Halbrook CJ and Lyssiotis CA. Cancer Cell 2017 - Review. PMID 28073003 Free article.
Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of cancer-related death. The high mortality rate results from a lack of methods for early detection and the inability to successfully treat patients once diagnosed. Pancreatic cancer cells have extensively reprogrammed metabolism, which is driven by oncogene-mediated cell-autonomous pathways, the unique physiology of the tumor microenvironment, and interactions with non-cancer cells. ...
Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of cancer-related death. The high mortality rat
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.
Sousa CM, et al. Nature 2016. PMID 27509858 Free PMC article.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by an intense fibrotic stromal response and deregulated metabolism. ...Here we show that stroma-associated pancreatic stellate cells (PSCs) are critical for PDAC metabolism through the secretion of non-essential amino acids (NEAA). ...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by an intense fibrotic stromal response and der
An overview of polyamine metabolism in pancreatic ductal adenocarcinoma.
Phanstiel O. Int J Cancer 2018 - Review. PMID 29134652 Free article.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of less than 8%. ...This review seeks to fill this void by describing what is currently known about polyamine metabolism in PDAC and identifies new targets and opportunities to treat this disease. ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of less than 8%.
Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P, et al. Gastroenterology 2018. PMID 29248441 Free PMC article.
BACKGROUND & AIMS: Activating mutations in KRAS are detected in most pancreatic ductal adenocarcinomas (PDACs). Expression of an activated form of KRAS (KrasG12D) in pancreata of mice is sufficient to induce formation of pancreatic intraepithelial neoplasia (PanINs)-a precursor of PDAC. ...Strategies to reduce KLF5 activity might reduce progression of acinar cells from ADM to PanIN and pancreatic tumorigenesis....
BACKGROUND & AIMS: Activating mutations in KRAS are detected in most pancreatic ductal adenocarcinomas (PDACs). Expression …
Molecular subtypes of pancreatic cancer.
Collisson EA, et al. Nat Rev Gastroenterol Hepatol 2019 - Review. PMID 30718832
Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. ...
Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, s …
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N, et al. Nat Commun 2018. PMID 30470748 Free PMC article.
Oncogenic KRAS is the key driver of pancreatic ductal adenocarcinoma (PDAC). We previously described a role for KRAS in PDAC tumor maintenance through rewiring of cellular metabolism to support proliferation. ...Together, these data reveal differential metabolic rewiring between KRAS-resistant and sensitive cells, and demonstrate that targeting nucleotide metabolism can overcome resistance to KRAS/MEK inhibition....
Oncogenic KRAS is the key driver of pancreatic ductal adenocarcinoma (PDAC). We previously described a role for KRAS in PDAC t …
The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance.
Biancur DE and Kimmelman AC. Biochim Biophys Acta Rev Cancer 2018 - Review. PMID 29702208 Free PMC article.
Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer that is highly refractory to the current standards of care. The difficulty in treating this disease is due to a number of different factors, including altered metabolism. ...
Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer that is highly refractory to the current standards of care. The
Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis.
Crawford HC, et al. Gastroenterology 2019 - Review. PMID 30716326 Free PMC article.
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, and its incidence on the rise. The major challenges in overcoming the poor prognosis with this disease include late detection and the aggressive biology of the disease. Intratumoral heterogeneity; presence of a robust, reactive, and desmoplastic stroma; and the crosstalk between the different tumor components require complete understanding of the pancreatic tumor biology to better understand the therapeutic challenges posed by this disease. ...
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, and its incidence on the rise. The major challenges in overc
Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
Pramanik KC, et al. Int J Mol Sci 2018 - Review. PMID 30563089 Free PMC article.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third highest among cancer related deaths. Despite modest success with therapy such as gemcitabine, pancreatic cancer incidence remains virtually unchanged in the past 25 years. ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third highest among cancer related deaths.
Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis
von Karstedt S, et al. Cancer Cell 2015. PMID 25843002 Free PMC article.
Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-driven models of non-small-cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) reduces tumor growth, blunts metastasis, and prolongs survival by inhibiting cancer cell-autonomous migration, proliferation, and invasion. ...
Cancer cell-restricted genetic ablation of murine TRAIL-R in autochthonous KRAS-driven models of non-small-cell lung cancer (NSCLC) and p
1,251 results
Jump to page
Feedback